drugset / Trial / NCT07522970
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LG-0317 in Healthy Participants
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is the first administration of LG-0317 to humans. The purpose of the study is to evaluate safety/tolerability and pharmacokinetics in healthy subjects. The intention of this study is to provide confidence in the safety of the molecule to inform progression to further proof-of-concept studies.
Timeline
- Start
- 2026-04-20
- Primary completion
- 2026-09-10
- Completion
- 2026-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LG-0317 | Unknown | — | Oral |
Indications
No indication recorded.